22nd Jul 2020 14:20
Diaceutics PLC - Belfast-based diagnostic commercialisation company - Announces a new USD1.8 million client contract with an unnamed pharmaceutical company. Diaceutics will produce commercial solutions for the client's US market using Diaceutics' new DXRX platform to improve patient testing and support the client's activities in the field of immunotherapy. Diaceutics Chief Executive said: "This client win marks another milestone in the commercial success of Diaceutics. Our data and new commercialisation platform DXRX are designed to provide a full end-to-end service, and via these we believe we are well placed to significantly improve patient testing for our clients' therapy in this challenging cancer setting."
Current stock price: 172.75
Year-to-date change: up 69%
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Diaceutics